Targeting mTORC1 and AMPK Signaling: Potential Therapeutic Approaches for Idiopathic Pulmonary Fibrosis
Doudou Chen , Yu Liu , Zhihao Xu
Advances in World Medical Research ›› 2026, Vol. 2 ›› Issue (1) : 1 -20.
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disease characterized by increasing incidence and mortality. The underlying mechanisms of IPF remain poorly understood, contributing to the limited availability of effective treatments. Current therapies mainly slow disease progression but fail to provide a cure. Consequently, increasing attention has been directed toward modulating signaling pathways such as mammalian target of rapamycin complex 1(mTORC1) and Adenosine monophosphate-activated protein kinase (AMPK), both of which are key regulators of metabolic reprogramming in IPF. This review summarizes recent advances in therapeutic strategies that target cellular metabolism by modulating mTORC1 and AMPK.
Idiopathic Pulmonary Fibrosis / AMPK / mTORC1 / Metabolic Reprogramming
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
|
| [80] |
|
/
| 〈 |
|
〉 |